Prof Leica Sequist gives a press conference at AACR 2019 about the results from the TATTON study, which examined the combination of osimertinib (a tyrosine kinase inhibitor/TKI) with savolitinib (a MET inhibitor) in patients with EGFR-mutant positive NSCLC.

One arm of the study consisted of patients who had developed MET-resistance after receiving a prior first or second generation EGFR TKI with MET-driven resistance.

The second arm of the study contained a cohort of patients who developed MET-driven resistance after receiving a third generation EGFR TKI.

Prof Sequist reports the response rates, associated side effects, anti-tumour activity and the safety profile of the osimertinib plus savolitinib regimen.